5-(吡啶-3-基)-1H-吡唑-3-甲酸乙酯 | 251658-58-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-(吡啶-3-基)-1H-吡唑-3-甲酸乙酯
• 英文名称: 3-(pyridin-3-yl)-1H-pyrazole-5-carboxylic acid ethyl ester
• 英文别名: ethyl 3-(pyridin-3-yl)-1H-pyrazole-5-carboxylate；ethyl 3-pyridin-3-yl-1H-pyrazole-5-carboxylate；5-ethoxycarbonyl-3-(3-pyridyl)pyrazole
• CAS: 251658-58-9
• 化学式: C₁₁H₁₁N₃O₂
• mdl: MFCD17193475
• 分子量: 217.227
• InChiKey: PHRDPBKZRMDSTI-UHFFFAOYSA-N

物化性质

• 熔点：
  162-163 °C
• 沸点：
  455.9±35.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-(pyridin-3-yl)-1H-pyrazole-5-carboxylate
Synonyms: Ethyl 5-(pyridin-3-yl)-1H-pyrazole-3-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-(pyridin-3-yl)-1H-pyrazole-5-carboxylate
CAS number: 251658-58-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H11N3O2
Molecular weight: 217.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(吡啶-3-基)-1H-吡唑-3-甲酸乙酯 在 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 sodium hydride 、 cobalt(II) chloride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(Pyridin-3-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
  参考文献：
  名称：

  4,5,6,7-四氢吡唑并吡嗪作为代谢型谷氨酸受体5负构构调节剂的合成，构效关系和生物学评估。

  摘要：

  这封信介绍了作为代谢型谷氨酸受体5（mGluR5）负变构调节剂（NAM）的新型4,5,6,7-四氢吡唑并吡嗪的设计，合成和SAR研究。从HTS命中化合物（1，IC50 = 477nM）开始，各种基团的优化导致合成了有效的mGluR5 NAM（32，IC50 = 75nM），具有出色的大鼠PK谱和良好的脑渗透性。该化合物在小鼠悬浮液模型（MED：30mg / kg）中产生了口服抗抑郁药样作用。

  DOI：

  10.1016/j.bmcl.2016.07.019
• 作为产物：
  描述：

  3-乙酰基吡啶 在 hydrazine hydrate 、 sodium methylate 作用下， 以 四氢呋喃 、 溶剂黄146 为溶剂， 反应 3.0h， 生成 5-(吡啶-3-基)-1H-吡唑-3-甲酸乙酯
  参考文献：
  名称：

  Three coordination polymers of transition metals built using HPPC ligand: Crystal structures and novel topology

  摘要：

  A new pyrazole-carboxylate type ligand, 3-(pyridin-3-yl)-1H-pyrazole-5-carboxylic acid (HPPC) was prepared from 3-acetylpyridine, diethyl oxalate and hydrazine hydrate. By employing this ligand, three new coordination complexes were prepared under solvothermal conditions: {[Ni(PPC)(2)]center dot 3H(2)O}(n) (1), [Ag(PPC)](n) (2) and [Cd(PPC)Cl](n) (3). Single-crystal X-ray diffraction analyses reveal that 1-3 exhibit three different structural types. Complex 1 displays a 4-connected net with the Schlafli symbol (4(4).6(2)) topology, several types of hydrogen bonds connect the 2-D layer to a 3-D structure. Complex 2 is built from [Ag(N2O)] clusters and PPC ligand as 3-connected linker with Schlafli symbol {3(6).4(6).5(3)}without consideration of Ag center dot center dot center dot Ag interaction. The 2-D networks are also linked to form 3 D framework via Ag center dot center dot center dot Ag interaction. Complex 3 can be regarded as a (3, 3)-connected net with the Schlafli symbol {3(33).4(33)} which consists of [Cd(N2O2)] clusters and PPC ligand as 3-connected bridge. The layers are further linked by the cholride atoms to generate a 3-D network. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2014.05.040

文献信息

• NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
  申请人：Bischoff Alexander

  公开号：US20100160323A1

  公开（公告）日：2010-06-24

  The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

  本发明涉及作为硬脂酰辅酶A去饱和酶抑制剂的哌嗪衍生物。该发明还涉及制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• ANDROGEN RECEPTOR MODULATING COMPOUNDS
  申请人：Wohlfahrt Gerd

  公开号：US20120225867A1

  公开（公告）日：2012-09-06

  The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

  本公开涉及式(I)的化合物及其药学上可接受的盐。本公开还涉及包括式(I)的化合物及其药学上可接受的盐的组合物和治疗方法。
• Androgen receptor modulating compounds
  申请人：Wohlfahrt Gerd

  公开号：US08975254B2

  公开（公告）日：2015-03-10

  The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

  本公开涉及式(I)的化合物及其药学上可接受的盐。本公开还涉及包含式(I)的化合物及其药学上可接受的盐的组合物和治疗方法。
• PYRAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS
  申请人：MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

  公开号：US20150057247A1

  公开（公告）日：2015-02-26

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

  本文提供了公式（I）的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露。这些化合物及其含量的制药组合物对于治疗退行性疾病和紊乱是有用的。
• Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
  申请人：MUSC Foundation for Research Development

  公开号：US08921401B2

  公开（公告）日：2014-12-30

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

  以下是公式（I）的化合物及其药学上可接受的盐，其中取代基如规范中所披露的。这些化合物和包含它们的药物组合物，可用于治疗退行性疾病和障碍。